Cargando…

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial

BACKGROUND: To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1–3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC). METHODS: This phase I study followed the rule of traditional 3 + 3 design. Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Kai-Lin, Chi, Mau-Shin, Ko, Hui-Ling, Huang, Yi-Ying, Huang, Su-Chen, Lin, Yu-Min, Chi, Kwan-Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819176/ https://www.ncbi.nlm.nih.gov/pubmed/33472666 http://dx.doi.org/10.1186/s13014-020-01742-w

Ejemplares similares

Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
por: Chi, Mau-Shin, et al.
Publicado: (2020)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
por: Oh, Do-Youn, et al.
Publicado: (2015)

Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy
por: Wang, Yu-Shan, et al.
Publicado: (2012)

Frontal skull craniotomy combined with moderate-dose radiotherapy effectively ameliorate a rare case of non-secretory, multiple myeloma with orbital involvement
por: Ko, Hui-Ling, et al.
Publicado: (2009)

Methicillin-resistant Staphylococcus aureus Necrotizing Bronchitis after Radiotherapy in Combination with Axitinib
por: Nakatsumi, Hiroki, et al.
Publicado: (2022)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma
por: Nouso, Kazuhiro, et al.
Publicado: (2020)

Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma
por: Shen, Jie, et al.
Publicado: (2017)

Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
por: Chi, Kwan-Hwa, et al.
Publicado: (2015)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
por: Jiang, Hao, et al.
Publicado: (2023)

Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients
por: Chi, Mau-Shin, et al.
Publicado: (2015)

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
por: Solomon, Benjamin, et al.
Publicado: (2022)

Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report
por: Chang, Yueh-Shih, et al.
Publicado: (2023)

Reciprocal Complementation of the Tumoricidal Effects of Radiation and Natural Killer Cells
por: Yang, Kai-Lin, et al.
Publicado: (2013)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
por: Deshpande, Hari A, et al.
Publicado: (2010)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Inhomogeneously distributed ferroptosis with a high peak-to-valley ratio may improve the antitumor immune response
por: Chi, Mau-Shin, et al.
Publicado: (2023)

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
por: Bondarenko, Igor M, et al.
Publicado: (2015)

A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma
por: Abei, Masato, et al.
Publicado: (2013)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
por: Ioka, Tatsuya, et al.
Publicado: (2015)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer
por: Li, Ning, et al.
Publicado: (2018)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
por: Koie, Takuya, et al.
Publicado: (2013)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
por: Gurruchaga Sotés, Ibon, et al.
Publicado: (2021)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rpikhaf6ols9d0k1bc9f5ddpgo